Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms BJG-03-144 |
Action degraders |
Mechanism alpha-tubulin degraders(Tubulin alpha degraders), β-tubulin degraders(tubulin beta class I degraders) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC41H50N4O12 |
InChIKeyWJAYRCUALBRAAI-HJWRWDBZSA-N |
CAS Registry- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | United States | 27 Apr 2020 | |
Neoplasms | Preclinical | United States | 27 Apr 2020 |